← Back to Search

Topoisomerase I inhibitor

Nitrocamptothecin for Colorectal Cancer

Phase 2

Waitlist Available

Research Sponsored by Astex Pharmaceuticals, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No more than 1 prior fluorouracil based chemotherapy regimen for metastatic disease

At least 1 bidimensionally measurable indicator lesion that has not been irradiated and meets specific size criteria for different types of lesions

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well nitrocamptothecin works in treating patients with colorectal cancer that has spread or returned.

Who is the study for?

This trial is for patients with advanced or recurrent colorectal cancer who have previously been treated with fluorouracil-based chemotherapy. They must have at least one measurable tumor and normal organ function, not be pregnant or nursing, and agree to use contraception. Patients who've had certain other treatments like nitrocamptothecin are excluded.Check my eligibility

What is being tested?

The study is testing the effectiveness of a chemotherapy drug called nitrocamptothecin in patients with colorectal cancer that has either come back or hasn't responded to previous treatment. It's a Phase II trial, which means it focuses on how well the drug works and monitors side effects.See study design

What are the potential side effects?

While specific side effects for nitrocamptothecin aren't listed here, common ones from similar chemotherapy drugs include nausea, vomiting, diarrhea, fatigue, low blood counts leading to increased infection risk, liver issues, and potential allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have had only one chemotherapy with fluorouracil for my advanced cancer.

Select...

I have a cancer lesion that can be measured in two directions and hasn't been treated with radiation.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Astex Pharmaceuticals, Inc.Lead Sponsor

95 Previous Clinical Trials

7,961 Total Patients Enrolled

Show-Li Sun, MDStudy ChairAstex Pharmaceuticals, Inc.

7 Previous Clinical Trials

113 Total Patients Enrolled

Media Library

Nitrocamptothecin (Topoisomerase I inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00005877 — Phase 2

Colorectal Cancer Research Study Groups:

Colorectal Cancer Clinical Trial 2023: Nitrocamptothecin Highlights & Side Effects. Trial Name: NCT00005877 — Phase 2

Nitrocamptothecin (Topoisomerase I inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00005877 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still vacancies available to join this research?

"Clinicaltrials.gov states that this medical trial, which first began on September 1st 1999 and was last updated in December 2013, is not presently enrolling patients. Despite the lack of new participants for this study, there are 1064 other clinical studies actively accepting volunteers at the moment."

Answered by AI

To what extent does this intervention pose risk to patients?

"Our team at Power has tentatively rated the safety of this treatment a 2 due to the lack of data on efficacy, despite Phase 2 trials suggesting some evidence for its security."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer

1999. "Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00005877.

All > Lynch Syndrome > Rectal Cancer